Methods for Predicting Human Drug Metabolism

Advances in Clinical Chemistry

Volumn 43, Issue , 2007, Pages 131-176

  Jolivette, Larry J ^a   Ekins, Sean ^b,c  

^a GLAXOSMITHKLINE   (United States)

^b ACT LLC   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

BIOLOGICAL MODEL; COMPUTER SIMULATION; HUMAN; METABOLISM; PHARMACOKINETICS; REVIEW;

COMPUTER SIMULATION; HUMANS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 33845640084     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2423(06)43005-5     Document Type: Review

References (315)

1. Leibman K. Drug metabolism: Prospects for the future. Drug Metab Rev 10 (1979) 299-309
2. Doucet J., Chassagne P., Trivalle C., Landrin I., Pauty M., Kadri N., et al. Drug-drug interactions related to hospital admissions in older adults: A prospective study of 1000 patients. J Am Geriatr Soc 44 (1996) 944-948
3. Yee J., Hasson N., and Schreiber D. Drug-related emergency department visits in an elderly veteran population. Ann Pharmacother 39 (2005) 1990-1994
4. Pezalla E. Preventing adverse drug reactions in the general population. Manag Care Interface 18 (2005) 49-52
5. Zhan C., Correa-de-Araujo R., Bierman A., Sangl J., Miller M., Wickizer S., et al. Suboptimal prescribing in elderly outpatients: Potentially harmful drug-drug and drug-disease combinations. J Am Geriatr Soc 53 (2005) 262-267
6. Klarin I., Wimo A., and Fastbom J. The association of inappropriate drug use with hospitalisation and mortality: A population-based study of the very old. Drugs Aging 22 (2005) 69-82
7. Smith D., and Obach R. Seeing through the mist: Abundance versus percentage. Commentary on metabolites in safety testing. Drug Metab Dispos 33 (2005) 1409-1417
8. White R. Short- and long-term projections about the use of drug metabolism in drug discovery and development. Drug Metab Dispos 26 (1998) 1213-1216
9. Austel V., and Kutter E. Absorption, distribution, and metabolism of drugs. In: Topliss J. (Ed). Quantitative Structure-Activity Relationships of Drugs (1983), Academic Press, New York 437-496
10. Paine M., Khalighi M., Fisher J., Shen D., Kunze K., Marsh C., et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283 (1997) 1552-1562
11. Williams J., Hyland R., Jones B., Smith D., Hurst S., Goosen T., et al. Drug-drug interactions for UDP-glucuronosyltransferase substrates: A pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32 (2004) 1201-1208
12. Ekins S., Maenpaa J., and Wrighton S. In vitro metabolism: Subcellular fractions. In: Woolf T. (Ed). Handbook of Drug Metabolism (1999), Marcel Dekker, New York 363-399
13. Ekins S., Ring B., Grace J., McRobie-Belle D., and Wrighton S. Present and future in vitro approaches for drug metabolism. J Pharmacol Toxicol Methods 44 (2000) 313-324
14. Ekins S., Ring B., Bravi G., Wikel J., and Wrighton S. Predicting drug-drug interactions in silico using pharmacophores: A paradigm for the next millennium. In: Guner O. (Ed). Pharmacophore Perception, Development, and Use in Drug Design (2000), IUL, San Diego 269-299
15. Ekins S., and Obach R. Three dimensional-quantitative structure activity relationship computational approaches of prediction of human in vitro intrinsic clearance. J Pharmacol Exp Ther 295 (2000) 463-473
16. Pelkonen O., Turpeinen M., Uusitalo J., Rautio A., and Raunio H. Prediction of drug metabolism and interactions on the basis of in vitro investigations. Basic Clin Pharmacol Toxicol 96 (2005) 167-175
17. Wienkers L., and Heath T. Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4 (2005) 825-833
18. Bachmann K., and Ghosh R. The use of in vitro methods to predict in vivo pharmacokinetics and drug interactions. Curr Drug Metab 2 (2001) 299-314
19. Venkatakrishnan K., von Moltke L., Obach R., and Greenblatt D. Drug metabolism and drug interactions: Application and clinical value of in vitro models. Curr Drug Metab 4 (2003) 423-459
20. Yao C., and Levy R. Inhibition-based metabolic drug-drug interactions: Predictions from in vitro data. J Pharm Sci 91 (2002) 1923-1935
21. Yan Z., and Caldwell G. Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery. Curr Top Med Chem 1 (2001) 403-425
22. White R. High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery. Annu Rev Pharmacol Toxicol 40 (2000) 133-157
23. Rodrigues A. Integrated cytochrome P450 reaction phenotyping: Attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 57 (1999) 465-480
24. Williams J., Hurst S., Bauman J., Jones B., Hyland R., Gibbs J., et al. Reaction phenotyping in drug discovery: Moving forward with confidence?. Curr Drug Metab 4 (2003) 527-534
25. Bjornsson T., Callaghan J., Einolf H., Fischer V., Gan L., Grimm S., et al. The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31 (2003) 815-832
26. Pritchard J., Jurima-Romet M., Reimer M., Mortimer E., Rolfe B., and Cayen M. Making better drugs: Decision gates in non-clinical drug development. Nat Rev Drug Discov 2 (2003) 542-553
27. Williams J., Bauman J., Cai H., Conlon K., Hansel S., Hurst S., et al. In vitro ADME phenotyping in drug discovery. Current challenges and future solutions. Curr Opin Drug Discov Devel 8 (2005) 78-88
28. Masimirembwa C., Thompson R., and Andersson T. In vitro high throughput screening of compounds for favorable metabolic properties in drug discovery. Comb Chem High Throughput Screen 4 (2001) 245-263
29. Thompson T. Early ADME in support of drug discovery: The role of metabolic stability studies. Curr Drug Metab 1 (2000) 215-241
30. Ansede J., and Thakker D. High-throughput screening for stability and inhibitory activity of compounds toward cytochrome P450-mediated metabolism. J Pharm Sci 93 (2004) 239-255
31. Di L., Kerns E., Hong Y., Kleintop T., McConnell O., and Huryn D. Optimization of a higher throughput microsomal stability screening assay for profiling drug discovery candidates. J Biomol Screen 8 (2003) 453-462
32. Eddershaw P., and Dickins M. Advances in in vitro drug metabolism screening. Pharm Sci Technol Today 2 (1999) 13-19
33. Janiszewski J., Rogers K., Whalen K., Cole M., Liston T., Duchoslav E., et al. A high-capacity LC/MS system for the bioanalysis of samples generated from plate-based metabolic screening. Anal Chem 73 (2001) 1495-1501
34. Zhao S., Forman D., Wallace N., Smith B., Meyer D., Kazolias D., et al. Simple strategies for reducing sample loads in in vitro metabolic stability high-throughput screening experiments: A comparison between traditional, two-time-point and pooled sample analyses. J Pharm Sci 94 (2005) 38-45
35. Sinz M. Drug metabolism in preclinical development. Applications of Pharmacokinetic Principles in Drug Development (2004), Kluwer Academic, New York 75-132
36. Wring S., Silver I., and Serabjit-Singh C. Automated quantitative and qualitative analysis of metabolic stability: A process for compound selection during drug discovery. Methods Enzymol 357 (2002) 285-295
37. Shibata Y., Takahashi H., and Ishii Y. A convenient in vitro screening method for predicting in vivo drug metabolic clearance using isolated hepatocytes suspended in serum. Drug Metab Dispos 28 (2000) 1518-1523
38. Lam J., and Benet L. Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: Studies of digoxin metabolism in primary rat hepatocytes versus microsomes. Drug Metab Dispos 32 (2004) 1311-1316
39. Ludden L., Ludden T., Collins J., Pentikis H., and Strong J. Effect of albumin on the estimation, in vitro, of phenytoin Vmax and Km values: Implications for clinical correlation. J Pharmacol Exp Ther 282 (1997) 391-396
40. Obach R. Nonspecific binding to microsomes: Impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. Drug Metab Dispos 25 (1997) 1359-1369
41. Tang C., Lin Y., Rodrigues A., and Lin J. Effect of albumin on phenytoin and tolbutamide metabolism in human liver microsomes: An impact more than protein binding. Drug Metab Dispos 30 (2002) 648-654
42. Crespi C., Miller V., and Stresser D. Design and application of fluorometric assays for human cytochrome P450 induction. Methods Enzymol 37 (1997) 276-284
43. Weaver R., Graham K., Beattie I., and Riley R. Cytochrome P450 inhibition using recombinant proteins and mass spectrometry/multiple reaction monitoring technology in a cassette incubation. Drug Metab Dispos 31 (2003) 955-966
44. Nomeir A., Ruegg C., Shoemaker M., Favreau L., Palamanda J., Silber P., et al. Inhibition of CYP3A4 in a rapid microtiter plate assay using recombinant enzyme and in human liver microsomes using conventional substrates. Drug Metab Dispos 29 (2001) 748-753
45. Bu H., Knuth K., Magis L., and Teitelbaum P. High-throughput cytochrome P450 inhibition screening via cassette probe-dosing strategy. IV. Validation of a direct injection on-line guard cartridge extraction/tandem mass spectrometry method for simultaneous CYP3A4, 2D6 and 2E1 inhibition assessment. Rapid Commun Mass Spectrom 14 (2000) 1943-1948
46. Wynalda M., and Wienkers L. Assessment of potential interactions between dopamine agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. Drug Metab Dispos 25 (1997) 1211-1214
47. Gao F., Johnson D., Ekins S., Janiszewski J., Kelly K., Meyer R., et al. Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6 and CYP3A4 in vitro using a single point IC50. J Biomol Screen 7 (2002) 373-382
48. Trubetskoy O., Gibson J., and Marks B. Highly miniaturized formats for in vitro drug metabolism assays using vivid fluorescent substrates and recombinant human cytochrome P450 enzymes. J Biomol Screen 10 (2005) 56-66
49. Stresser D., Blanchard A., Turner S., Erve J., Dandeneau A., Miller V., et al. Substrate-dependent modulation of CYP3A4 catalytic activity: Analysis of 27 test compounds with four fluorimetric substrates. Drug Metab Dispos 28 (2000) 1440-1448
50. Boase S., and Miners J. In vitro-in vivo correlations for drugs eliminated by glucuronidation. Investigations with the model substrate zidovudine. Br J Clin Pharmacol 54 (2002) 493-503
51. Carlile D., Hakooz N., Bayliss M., and Houston J. Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans. Br J Clin Pharmacol 47 (1999) 625-635
52. Ito K., Iwatsubo T., Kanamitsu S., Nakajima Y., and Sugiyama Y. Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu Rev Pharmacol Toxicol 38 (1998) 461-499
53. Iwatsubo T., Hirota N., Ooie T., Suzuki H., Shimada N., Chiba K., et al. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 73 (1997) 147-171
54. Jones H., and Houston J. Substrate depletion approach for determining in vitro metabolic clearance: Time dependencies in hepatocyte and microsomal incubations. Drug Metab Dispos 32 (2004) 973-982
55. Naritomi Y., Terashita S., Kimura S., Suzuki A., Kagayama A., and Sugiyama Y. Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos 29 (2001) 1316-1324
56. Andersson T., Sjoberg H., Hoffmann K., Boobis A., Watts P., Edwards R., et al. An assessment of human liver-derived in vitro systems to predict the in vivo metabolism and clearance of almokalant. Drug Metab Dispos 29 (2001) 712-720
57. Andersson T., Bredberg E., Ericsson H., and Sjoberg H. An evaluation of the in vitro metabolism data for predicting the clearance and drug-drug interaction potential of CYP2C9 substrates. Drug Metab Dispos 32 (2004) 715-721
58. Clarke S., and Jeffrey P. Utility of metabolic stability screening: Comparison of in vitro and in vivo clearance. Xenobiotica 31 (2001) 591-598
59. Mahmood I. Prediction of clearance in humans from in vitro human liver microsomes and allometric scaling. A comparative study of the two approaches. Drug Metabol Drug Interact 19 (2002) 49-64
60. Obach R. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and non specific binding to microsomes. Drug Metab Dispos 27 (1999) 1350-1359
61. Nagilla R., Frank K., Jolivette L., and Ward K. Investigation of the utility of published in vitro intrinsic clearance data for prediction of in vivo clearance. J Pharmacol Toxicol Methods 53 (2005) 106-116
62. Kalvass J., Tess D., Giragossian C., Linhares M., and Maurer T. Influence of microsomal concentration on apparent intrinsic clearance: Implications for scaling in vitro data. Drug Metab Dispos 29 (2001) 1332-1336
63. Yin H., Tran P., Greenberg G., and Fischer V. Methanol solvent may cause increased apparent metabolic instability in in vitro assays. Drug Metab Dispos 29 (2001) 185-193
64. Bachmann K., Byers J., and Ghosh R. Prediction of in vivo hepatic clearance from in vitro data using cryopreserved human hepatocytes. Xenobiotica 33 (2003) 475-483
65. McGinnity D., Soars M., Urbanowicz R., and Riley R. Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab Dispos 32 (2004) 1247-1253
66. Jolivette L., and Ward K. Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure. J Pharm Sci 94 (2005) 1467-1683
67. Ekins S. Predicting undesirable drug interactions with promiscuous proteins in silico. Drug Discov Today 9 (2004) 276-285
68. Lewis D. Cytochromes P450. Cytochromes P450 (1996), Taylor & Francis, Bristol
69. Anari M., and Baillie T. Bridging cheminformatic metabolite prediction and tandem mass spectrometry. Drug Discov Today 10 (2005) 711-777
70. Anari M., Sanchez R., Bakhtiar R., Franklin R., and Baillie T. Integration of knowledge-based metabolic predictions with liquid chromatography data-dependent tandem mass spectrometry for drug metabolism studies: Application to studies on the biotransformation of indinavir. Anal Chem 76 (2004) 823-832
71. Nassar A., and Talaat R. Strategies for dealing with metabolite elucidation in drug discovery and development. Drug Discov Today 9 (2004) 317-327
72. Lin T., Pang J., Hao C., Stranz D., Campbell S., Mordenti J., et al. Semi-automated metabolite identification using information-dependent LC/MS/MS acquisition, in silico metabolite prediction, and structure based data analysis. Drug Metab Rev 37 Suppl. 2 Abstract (2005) 399
73. Shu Y., Arora V., Alberts J., Belcastro J., and Skiles G. Bridging metabolite prediction and metabolite identification-the use of metabolite prediction software for LC/MS data mining of potential metabolites. Drug Metab Rev 36 Suppl. 1 (2004) 103
74. Kesuru G., and Molnar L. METAPRINT: A metabolic fingerprint. Application to cassette design for high-throughput ADME screening. J Chem Inf Comput Sci 42 (2002) 437-444
75. de Graaf C., Vermeulen N., and Feenstra K. Cytochrome P450 in silico: An integrative modeling approach. J Med Chem 48 (2005) 2725-2755
76. Hansch C., Deutsch E., and Smith R. The use of substituent constants and regression analysis in the study of enzymatic reaction mechanisms. J Am Chem Soc 87 (1965) 2738-2742
77. Hansch C., Steward A., and Iwasa J. The use of substituent constants in the correlation of demethylation rates. J Med Chem 8 (1965) 868-870
78. Hansch C. Quantitative relationships between lipophilic character and drug metabolism. Drug Metab Revs 1 (1972) 1-14
79. Hansch C. The QSAR paradigm in the design of less toxic molecules. Drug Metab Rev 15 (1984) 1279-1294
80. Hansch C., Lien E., and Helmer F. Structure-activity correlations in the metabolism of drugs. Arch Biochem Biophys 128 (1968) 319-330
81. Hansch C., and Zhang L. Quantitative structure-activity relationships of cytochrome P-450. Drug Metab Rev 25 (1993) 1-48
82. Lewis D. Quantitative structure activity relationships in substrates, inducers, and inhibitors of cytochrome P4501 (CYP1). Drug Metab Rev 29 (1997) 589-650
83. Lewis D. On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics. Biochem Pharmacol 60 (2000) 293-306
84. Lewis D. Structural characteristics of human P450s involved in drug metabolism: QSARs and lipophilicity profiles. Toxicology 144 (2000) 197-203
85. Lewis D., Eddershaw P., Dickins M., Tarbit M., and Goldfarb P. Structural determinants of cytochrome P450 substrate specificity, binding affinity and catalytic rate. Chem Biol Interact 115 (1998) 175-199
86. Lewis D., Eddershaw P., Dickins M., Tarbit M., and Goldfarb P. Erratum to structural determinants of cytochrome P450 substrate specificity, binding affinity and catalytic rate. Chem Biol Interact 117 (1999) 187
87. Lewis D., Jacobs M., and Dickins M. Compound lipophilicity for substrate binding to human P450s in drug metabolism. Drug Discov Today 9 (2004) 530-537
88. Ekins S., and Swaan P. Development of computational models for enzymes, transporters, channels and receptors relevant to ADME/TOX. Rev Comp Chem 20 (2004) 333-415
89. Fuhr U., Strobl G., Manaut F., Anders E., Sorgel F., Lopez-de-brinas E., et al. Quinolone antibacterial agents: Relationship between structure and in vitro inhibition of human cytochrome P450 isoform CYP1A2. Mol Pharmacol 43 (1993) 191-199
90. Jones J., and Korzekwa K. Predicting the Rates and Regioselectivity of Reactions Mediated by the P450 Superfamily (1996), Academic Press, Inc., New York
91. Locuson C., and Wahlstrom J. Three-dimensional quantitative structure-activity relationship analysis of cytochromes p450: Effect of incorporating higher-affinity ligands and potential new applications. Drug Metab Dispos 33 (2005) 873-888
92. Tukey R., and Strassburg C. Human UDP-glucuronosyltransferases: Metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40 (2000) 581-616
93. Ethell B., Ekins S., Wang J., and Burchell B. Quantitative structure activity relationships for the glucuronidation of simple phenols by expressed human UGT1A6 and UGT1A9. Drug Metab Dispos 30 (2002) 734-738
94. Sorich M., McKinnon R., Miners J., Winkler D., and Smith P. Rapid prediction of chemical metabolism by human UDP-glucuronosyltransferase isoforms using quantum chemical descriptors derived with the electronegativity equalization method. J Med Chem 47 (2004) 5311-5317
95. Dajani R., Cleasby A., Neu M., Wonacott A., Jhoti H., Hood A., et al. X-ray crystal structure of human dopamine sulfotransferase, SULT1A3. J Biol Chem 53 (1999) 37862-37868
96. Gamage N., Duggleby R., Barnett A., Tresillian M., Latham C., Liyou N., et al. Structure of a human carcinogen-converting enzyme, SULT1A1. J Biol Chem 278 (2003) 7655-7662
97. Rusinko III A., Farmen M., Lambert C., Brown P., and Young S. Analysis of a large structure/biological activity data set using recursive partitioning. J Chem Inf Comput Sci 39 (1999) 1017-1026
98. Ekins S. In silico approaches to predicting metabolism, toxicology and beyond. Biochem Soc Trans 31 (2003) 611-614
99. Shen M., Xiao Y., Golbraikh A., Gombar V., and Tropsha A. Development and validation of k-nearest neighbour QSPR models of metabolic stability of drug candidates. J Med Chem 46 (2003) 3013-3020
100. Jensen B., Sorensen M., Kissmeyer A., Bjorkling F., Sonne K., Engelsen S., et al. Prediction of in vitro metabolic stability of calcitriol analogs by QSAR. J Comput Aided Mol Des 17 (2003) 849-859
101. Kohonen T. Self-organisation and Associative Memory (1989), Springer-Verlag, Berlin
102. Balakin K., Ekins S., Bugrim A., Ivanenkov Y., Korolev D., Nikolsky Y., et al. Kohonen maps for prediction of binding to human cytochrome P450 3A4. Drug Metab Dispos 32 (2004) 1183-1189
103. Mitchell M. An Introduction to Genetic Algorithms (1996), MIT Press, Cambridge, MA
104. Balakin K., Ekins S., Bugrim A., Ivanenkov Y., Korolev D., Nikolsky Y., et al. Quantitative structure-metabolism relationship modeling of the metabolic N-dealkylation rates. Drug Metab Dispos 32 (2004) 1111-1120
105. Korolev D., Balakin K., Nikolsky Y., Kirillov E., Ivanenkov Y., Savchuk N., et al. Modeling of human cytochrome P450-mediated drug metabolism using unsupervised machine learning approach. J Med Chem 46 (2003) 3631-3643
106. Bugrim A., Nikolskaya T., and Nikolsky Y. Early prediction of drug metabolism and toxicity: Systems biology approach and modeling. Drug Discov Today 9 (2004) 127-135
107. Yao H., Costache A., and Sem D. Chemical proteomic tool for ligand mapping of CYP antitargets: An NMR-compatible 3D QSAR descriptor in the heme-based coordinate system. J Chem Inf Comput Sci 44 (2004) 1456-1465
108. Ekins S., de Groot M., and Jones J. Pharmacophore and three dimensional quantitative structure activity relationship methods for modeling cytochrome P450 active sites. Drug Metab Dispos 29 (2001) 936-944
109. Ekins S., VandenBranden M., Ring B., and Wrighton S. Examination of purported probes of human CYP2B6. Pharmacogenetics 7 (1997) 165-179
110. Ekins S., VandenBranden M., Ring B., Gillespie J., Yang T., Gelboin H., et al. Further characterization of the expression and catalytic activity of human CYP2B6. J Pharm Exp Ther 286 (1998) 1253-1259
111. Ekins S., Bravi G., Ring B., Gillespie T., Gillespie J., VandenBranden M., et al. Three dimensional-quantitative structure activity relationship (3D-QSAR) analyses of substrates for CYP2B6. J Pharm Exp Ther 288 (1999) 21-29
112. Ekins S., Bravi G., Wikel J., and Wrighton S. Three dimensional quantitative structure activty relationship (3D-QSAR) analysis of CYP3A4 substrates. J Pharmacol Exp Ther 291 (1999) 424-433
113. Ekins S., Bravi G., Binkley S., Gillespie J., Ring B., Wikel J., et al. Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors. Pharmacogenetics 9 (1999) 477-489
114. Ekins S., Bravi G., Binkley S., Gillespie J., Ring B., Wikel J., et al. Three and four dimensional-quantitative structure activity relationship analyses of CYP3A4 inhibitors. J Pharmacol Exp Ther 290 (1999) 429-438
115. Ekins S., Bravi G., Binkley S., Gillespie J., Ring B., Wikel J., et al. Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors. Drug Metab Dispos 28 (2000) 994-1002
116. Snyder R., Sangar R., Wang J., and Ekins S. Three dimensional quantitative structure activity relationship for CYP2D6 substrates. Quant Struct Act Relationship 21 (2002) 357-368
117. Ekins S., Stresser D., and Williams J. In vitro and pharmacophore insights into CYP3A enzymes. Trends Pharmacol Sci 24 (2003) 191-196
118. Ekins S., and Wrighton S. Application of in silico approaches to predicting drug-drug interactions: A commentary. J Pharmacol Toxicol Methods 44 (2001) 1-5
119. Asikainen A., Tarhanen J., Poso A., Pasanen M., Alhava E., and Juvonen R. Predictive value of comparative molecular field analysis modelling of naphthalene inhibition of human CYP2A6 and mouse CYP2A5 enzymes. Toxicol in vitro 17 (2003) 449-455
120. Wrighton S., Schuetz E., Thummel K., Shen D., Korzekwa K., and Watkins P. The human CYP3A subfamily: Practical considerations. Drug Metab Rev 32 (2000) 339-361
121. Ekins S., and Wrighton S. The role of CYP2B6 in human xenobiotic metabolism. Drug Metab Rev 31 (1999) 719-754
122. Ekins S., Berbaum J., and Harrison R. Generation and validation of rapid computational filters for CYP2D6 and CYP3A4. Drug Metab Dispos 31 (2003) 1077-1080
123. Locuson II C., Wahlstrom J., Rock D., Rock D., and Jones J. A new class of CYP2C9 inhibitors: Probing 2C9 specificity with high-affinity benzbromarone derivatives. Drug Metab Dispos 31 (2003) 967-971
124. Locuson II C., Rock D., and Jones J. Quantitative binding models for CYP2C9 based on benzbromarone analogues. Biochemistry 43 (2004) 6948-6958
125. Locuson II C., Suzuki H., Rettie A., and Jones J. Charge and substituent effects on affinity and metabolism of benzbromarone-based CYP2C19 inhibitors. J Med Chem 47 (2004) 6768-6776
126. Korzekwa K., Krishnamachary N., Shou M., Ogai A., Parise R., Rettie A., et al. Evaluation of atypical cytochrome P450 kinetics with two-substrate-models: Evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 37 (1998) 4137-4147
127. Ekins S., Ring B., Binkley S., Hall S., and Wrighton S. Autoactivation and activation of cytochrome P450s. Int J Clin Pharmacol Ther 36 (1998) 642-651
128. Atkins W. Non-Michaelis-Menten kinetics in cytochrome P450-catalyzed reactions. Annu Rev Pharmacol Toxicol 45 (2005) 291-310
129. Bauman J., Goosen T., Tugnait M., Peterkin V., Hurst S., Menning L., et al. Udp-glucuronosyltransferase 2b7 is the major enzyme responsible for gemcabene glucuronidation in human liver microsomes. Drug Metab Dispos 33 (2005) 1349-1354
130. Egnell A., Houston J., and Boyer C. Predictive models of CYP3A4 heteroactivation: In vitro-in vivo scaling and pharmacophore modelling. J Pharmacol Exp Ther 312 (2004) 926-937
131. Egnell A., Eriksson C., Albertson N., Houston B., and Boyer S. Generation and evaluation of a CYP2C9 heteroactivation pharmacophore. J Pharmacol Exp Ther 307 (2003) 878-887
132. Smith P., Sorich M., McKinnon R., and Miners J. QSAR and pharmacophore modelling approaches for the prediction of UDP-glucuronosyltransferase substrate selectivity and binding. The Pharmacologist 44 Suppl. (2002)
133. Smith P., Sorich M., McKinnon R., and Miners J. Pharmacophore and quantitative structure-activity relationship modeling: Complementary approaches for the rationalization and prediction of UDP-glucuronosyltransferase 1A4 substrate selectivity. J Med Chem 46 (2003) 1617-1626
134. Sorich M., Smith P., McKinnon R., and Miners J. Pharmacophore and quantitative structure activity relationship modelling of UDP-glucuronosyltransferase 1A1 (UGT1A1) substrates. Pharmacogenetics 12 (2002) 635-645
135. Smith P., Sorich M., McKinnon R., and Miners J. In silico insights: Chemical and structural characteristics associated with uridine diphosphate-glucuronosyltransferase substrate selectivity. Clin Exp Pharmacol Physiol 30 (2003) 836-840
136. Sorich M., Miners J., McKinnon R., and Smith P. Multiple pharmacophores for the investigation of human UDP-glucuronosyltransferase isoform substrate selectivity. Mol Pharmacol 65 (2004) 301-308
137. Miners J., Smith P., Sorich M., McKinnon R., and Mackenzie P. Predicting human drug glucuronidation parameters: Application of in vitro and in silico modeling approaches. Annu Rev Pharmacol Toxicol 44 (2004) 1-25
138. Wang Q., and Halpert J. Combined three-dimensional quantitative structure-activity relationship analysis of cytochrome P450 2B6 substrates and protein homology modeling. Drug Metab Dispos 30 (2002) 86-95
139. Jones J., Mysinger M., and Korzekwa K. Computational models for cytochrome P450: A predictive electronic model for aromatic oxidation and hydrogen abstraction. Drug Metab Dispos 30 (2002) 7-12
140. Singh S., Shen L., Walker M., and Sheridan R. A model for likely sites of CYP3A4-mediated metabolism on drug-like molecules. J Med Chem 46 (2003) 1330-1336
141. Csanady G., and Laib J. Metabolic transformation of halogenated and other alkenes-a theoretical approach. Estimation of metabolic reactivities for in vivo conditions. Toxicology 75 (1995) 217-223
142. Yin H., Anders M., Korzekwa K., Higgins L., Thummel K., Kharasch E., et al. Designing safer chemicals: Predicting the rates of metabolism of halogenated alkanes. Proc Natl Acad Sci USA 92 (1995) 11076-11080
143. Korzekwa K., Ewing T., Kocher J., and Carlson T. Models for cytochrome P450-mediated metabolism. In: Borchardt R., Kerns E., Lipinski C., Thakker D., and Wang B. (Eds). Pharmaceutical Profiling in Drug Discovery for Lead Selection (2004), AAPS Press, Arlington, VA 69-80
144. Bursi R., de Gooyer M., Grootenhuis A., Jacobs P., van der Louw J., and Leysen D. (Q)SAR study on the metabolic stability of steroidal androgens. J Mol Graph Model 19 (2001) 552-556
145. Cosme J., and Johnson E. Engineering microsomal cytochrome P450 2C5 to be a soluble, monomeric enzyme. Mutations that alter aggregation, phospholipid dependence of catalysis, and membrane binding. J Biol Chem 275 (2000) 2545-2553
146. Williams P., Cosme J., Ward A., Angove H., Matak Vinkovic D., and Jhoti H. Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 424 (2003) 464-468
147. Williams P., Cosme J., Sridhar V., Johnson E., and McRee D. Mammalian microsomal cytochrome P450 monooxygenase: Structural adaptations for membrane binding and functional diversity. Mol Cell 5 (2000) 121-131
148. Wester M., Yano J., Schoch G., Yang C., Griffin K., Stout C., et al. The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-Å resolution. J Biol Chem 279 (2004) 35630-35637
149. Wester M., Johnson E., Marques-Soares C., Dijols S., Dansette P., Mansuy D., et al. Structure of mammalian cytochrome P450 2C5 complexed with diclofenac at 2.1 Å resolution: Evidence for an induced fit model of substrate binding. Biochemistry 42 (2003) 9335-9345
150. Schoch G., Yano J., Wester M., Griffin K., Stout C., and Johnson E. Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site. J Biol Chem 279 (2004) 9497-9503
151. Melet A., Marques-Soares C., Schoch G., Macherey A., Jaouen M., Dansette P., et al. Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry 43 (2004) 15379-15392
152. Williams P., Cosme J., Vinkovic D., Ward A., Angove H., Day P., et al. Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science 305 (2004) 683-686
153. Yano J., Wester M., Schoch G., Griffin K., Stout C., and Johnson E. The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-Å resolution. J Biol Chem 279 (2004) 38091-38094
154. Koymans L., Vermeulen N., Baarslag A., and Donne-Op den Kelder G. A preliminary 3D model for cytochrome P450 2D6 constructed by homology model building. J Comput Aided Mol Des 7 (1993) 281-289
155. Modi S., Paine M., Sutcliffe M., Lian L., Primrose W., Wolf C., et al. A model for human cytochrome P4502D6 based on homology modeling and NMR studies of substrate binding. Biochemistry 35 (1996) 4540-4550
156. Lewis D., Lake B., Dickins M., Eddershaw P., Tarbit M., and Goldfarb P. Molecular modelling of CYP2B6, the human CYP2B isoform, by homology with the substrate-bound CYP102 crystal structure: Evaluation of CYP2B6 substrate characteristics, the cytochrome b5 binding site and comparisons with CYP2B1 and CYP2B4. Xenobiotica 29 (1999) 361-393
157. Szklarz G., and Halpert J. Use of homology modeling in conjunction with site-directed mutagenesis for analysis of structure-function relationships of mammalian cytochromes P450. Life Sci 61 (1997) 2507-2520
158. Szklarz G., and Halpert J. Molecular modeling of cytochrome P4503A4. J Comput Aided Mol Des 11 (1997) 265-272
159. Szklarz G., Graham S., and Paulsen M. Molecular modeling of mammalian cytochromes P450: Application to study enzyme function. Vitam Horm 58 (2000) 53-87
160. Lewis D., Eddershaw P., Goldfarb P., and Tarbit M. Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: Structural studies on specific CYP2D6 substrate metabolism. Xenobiotica 27 (1997) 319-340
161. Lewis D., Eddershaw P., Goldfarb P., and Tarbit M. Molecular modelling of CYP3A4 from an alignment with CYP102: Identification of key interactions between putative active site residues and CYP3A-specific chemicals. Xenobiotica 10 (1996) 1067-1086
162. Lewis D., Dickins M., Weaver R., Eddershaw P., Goldfarb P., and Tarbit M. Molecular modelling of human CYP2C subfamily enzymes CYP2C9 and CYP2C19: Rationalization of substrate specificity and site-directed mutagenesis experiments in the CYP2C subfamily. Xenobiotica 28 (1998) 235-268
163. Lewis D. Three-dimensional models of human and other mammalian microsomal P450s constructed from an alignment with P450102 (P450bm3). Xenobiotica 25 (1995) 333-366
164. Wiseman H., and Lewis D. The metabolism of tamoxifen by human cytochromes P450 is rationalized by molecular modelling of the enzyme substrate interactions: Potential importance to its proposed anti-carcingenic/carcinogenic actions. Carcinogenesis 17 (1996) 1357-1360
165. de Groot M., Bijloo G., Van Acker F., Fonseca Guerra C., Snijders J., and Vermeulen N. Extension of a predictive substrate model for human cytochrome P4502D6. Xenobiotica 27 (1997) 357-368
166. de Groot M., Bijloo G., Martens B., van Acker F., and Vermeulen N. A refined substrate model for human cytochrome P450 2D6. Chem Res Toxicol 10 (1997) 41-48
167. de Groot M., Alex A., and Jones B. Development of a combined protein and pharmacophore model for cytochrome P450 2C9. J Med Chem 45 (2002) 1983-1993
168. de Groot M., Ackland M., Horne V., Alex A., and Jones B. Novel approach to predicting P450-mediated drug metabolism: Development of a combined protein and pharmacophore model for CYP2D6. J Med Chem 42 (1999) 1515-1524
169. de Groot M., Ackland M., Horne V., Alex A., and Jones B. A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6. J Med Chem 42 (1999) 4062-4070
170. Salonen J., Nyman L., Boobis A., Edwards R., Watts P., Lake B., et al. Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. Drug Metab Dispos 31 (2003) 1093-1102
171. Renwick A., Lewis D., Fulford S., Surry D., Williams B., Worboys P., et al. Metabolism of 2,5-bis(trifluoromethyl)-7-benzyloxy-4-trifluoromethylcoumarin by human hepatic CYP isoforms: Evidence for selectivity towards CYP3A4. Xenobiotica 31 (2001) 187-204
172. Lewis D. Molecular modelling of cytochrome P450. In: van de Waterbeemd H., Testa B., and Folkers G. (Eds). Computer Assisted Lead Finding and Optimization (1997), Wiley-VCH, Weinheim 335-354
173. Afzelius L., Zamora I., Ridderstrom M., Andersson T., Karlen A., and Masimirembwa C. Competitive CYP2C9 inhibitors: Enzyme inhibition studies, protein homology modeling, and three dimensional quantitative structure activity relationship analysis. Mol Pharmacol 59 (2001) 909-919
174. Barhelt C., Schmid R., and Pleiss J. Regioselectivity of CYP2B6: Homology modeling, molecular dynamics simulation, docking. J Mol Model 8 (2002) 327-335
175. Keizers P., de Graaf C., de Kanter F., Oostenbrink C., Feenstra K., Commandeur J., et al. Metabolic regio- and stereoselectivity of cytochrome P450 2D6 towards 3,4-methylenedioxy-N-alkylamphetamines: In silico predictions and experimental validation. J Med Chem 48 (2005) 6117-6127
176. Kemp C., Flanagan J., van Eldik A., Marechal J., Wolf C., Roberts G., et al. Validation of model of cytochrome P450 2D6: An in silico tool for predicting metabolism and inhibition. J Med Chem 47 (2004) 5340-5346
177. Marechal J., Yu J., Brown S., Kapelioukh I., Rankin E., Wolf C., et al. In silico and in vitro screening for inhibition of cytochrome P450 CYP3A4 by co-medications commonly used by patients with cancer. Drug Metab Dispos 34 (2006) 534-538
178. Lill M., Dobler M., and Vedani A. Prediction of small-molecule binding to cytochrome P450 3A4: Flexible docking combined with multidimensional QSAR. Chem Med Chem 6 (2005) 1-10
179. Zhou D., Afzelius L., Grimm S., Andersson T., Zauhar R., and Zamora I. Comparison of methods for the prediction of the metabolic sites for CYP3A4-mediated metabolic reactions. Drug Metab Dispos 34 (2006) 976-983
180. Johnson E., and Stout C. Structural diversity of human xenobiotic-metabolizing cytochrome P450 monooxygenases. Biochem Biophys Res Commun 338 (2005) 331-336
181. Kirton S., Baxter C., and Sutcliffe M. Comparative modelling of the cytochromes P450. Adv Drug Deliv Rev 54 (2002) 385-406
182. Kliewer S., Moore J., Wade L., Staudinger J., Watson M., Jones S., et al. An orphan nuclear receptor activated by pregnanes defines a novel steroid signalling pathway. Cell 92 (1998) 73-82
183. Nakata K., Yukawa M., Komiyama N., Nakano T., and Kaminuma T. A nuclear receptor database that maps pathways to diseases. Genome Inform 13 (2002) 515-516
184. Schapira M., Raaka B., Samuels H., and Abagyan R. Rational discovery of novel nuclear hormone receptor antagonists. Proc Natl Acad Sci USA 97 (2000) 1008-1013
185. Sun L., Ji Z., Chen X., Wang J., and Chen Y. ADME-AP: A database of ADME associated proteins. Bioinformatics 18 (2002) 1699-1700
186. Erhardt P. A human drug metabolism database: Potential roles in the quantitative predictions of drug metabolism and metabolism-related drug-drug interactions. Curr Drug Metab 4 (2003) 411-422
187. Boyer S., and Zamora I. New methods in predictive metabolism. J Comput Aided Mol Des 16 (2002) 403-413
188. Borodina Y., Sadym A., Filimonov D., Blinova V., Dmitriev A., and Poroikov V. Predicting biotransformation potential from molecular structure. J Chem Inf Comput Sci 43 (2003) 1636-1646
189. Borodina Y., Rudik A., Filimonov D., Kharchevnikova N., Dmitriev A., Blinova V., et al. A new statistical approach to predicting aromatic hydroxylation sites. Comparison with model-based approaches. J Chem Inf Comput Sci 44 (2004) 1998-2009
190. Wishart D., Knox C., Guo A., Shrivastava S., Hassanali M., Stothard P., et al. DrugBank: A comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 34 (2006) D668-D672
191. Hawkins D. Metabolism databases: Their use and value. Med Chem Res 8 (1998) 434-443
192. Erhardt P. A human drug metabolism database: Potential roles in the quantitative predictions of drug metabolism and metabolism-related drug-drug interactions. Curr Drug Metab 4 (2003) 411-422
193. Smith R., Erhardt P., and Leslie S. Microsomal O-demethylation, N-demethylation and aromatic hydroxylation in the presence of bisulfite and dithiothreitol. Res Commun Chem Pathol Pharmacol 12 (1975) 181-184
194. Darvas F., Dorman G., and Papp A. Diversity measures for enhancing ADME admissibility of combinatorial libraries. J Chem Inf Comput Sci 40 (2000) 314-322
195. Darvas F. Predicting metabolic pathways by logic programming. J Mol Graph 6 (1988) 80-86
196. Klopman G., Dimayuga M., and Talafous J. META. 1. A program for the evaluation of metabolic transformations of chemicals. J Chem Inf Comput Sci 34 (1994) 1320-1325
197. Talafous J., Sayre L., Mieyal J., and Klopman G. META. 2. A dictionary model of mammalian xenobiotic metabolism. J Chem Inf Comput Sci 34 (1994) 1326-1333
198. Klopman G., Tu M., and Talafous J. META. 3. A genetic algorithm for metabolic transform priorities optimization. J Chem Inf Comput Sci 37 (1997) 329-334
199. Langowski J., and Long A. Computer systems for the prediction of xenobiotic metabolism. Adv Drug Deliv Rev 54 (2002) 407-415
200. Button W., Judson P., Long A., and Vessey J. Using absolute and relative reasoning in the prediction of the potential metabolism of xenobiotics. J Chem Inf Comput Sci 43 (2003) 1371-1377
201. Hou B., Ellis L., and Wackett L. Encoding microbial metabolic logic: Predicting biodegradation. J Ind Microbiol Biotechnol 31 (2004) 261-272
202. Hou B., Wackett L., and Ellis L. Microbial pathway prediction: A functional group approach. J Chem Inf Comput Sci 43 (2003) 1051-1057
203. Ellis L., Hou B., Kang W., and Wackett L. The University of Minnesota Biocatalysis/Biodegradation Database: Post-genomic data mining. Nucleic Acids Res 31 (2003) 262-265
204. Ellis L., Roe D., and Wackett L. The University of Minnesota Biocatalysis/Biodegradation Database: The first decade. Nucleic Acids Res 34 (2006) D517-D521
205. Mekenyan O., Dimitrov S., Pavlov T., and Veith G. A systematic approach to simulating metabolism in computational toxicology. I. The TIMES heuristic modelling framework. Curr Pharm Des 10 (2004) 1273-1293
206. Kulkarni S., Zhu J., and Blechinger S. In silico techniques for the study and prediction of xenobiotic metabolism: A review. Xenobiotica 35 (2005) 955-973
207. Berellini G., Cruciani G., and Mannhold R. Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists. J Med Chem 48 (2005) 4389-4399
208. Cruciani G., Carosati E., De Boeck B., Ethirajulu K., Mackie C., Howe T., et al. MetaSite: Understanding metabolism in human cytochromes from the perspective of the chemist. J Med Chem 48 (2005) 6970-6979
209. Ekins S., Andreyev S., Ryabov A., Kirillov E., Rakhmatulin E., Sorokina S., et al. A combined approach to drug metabolism and toxicity assessment. Drug Metab Dispos 34 (2006) 495-503
210. Young S., Ekins S., and Lambert C. So many targets, so many compounds, but so few resources. Curr Drug Discov (2002) 17-22 December
211. Young S., Gombar V., Emptage M., Cariello N., and Lambert C. Mixture deconvolution and analysis of Ames mutagenicity data. Chemo Intell Lab Syst 60 (2002) 5-11
212. Li A. A review of the common properties of drugs with idiosyncratic hepatotoxicity and the "multiple determinant hypothesis" for the manifestation of idiosyncratic drug toxicity. Chem Biol Interact 142 (2002) 7-23
213. Williams D., and Park B. Idiosyncratic toxicity: The role of toxicophores and bioactivation. Drug Discov Today 8 (2003) 1044-1050
214. Uetrecht J. Screening for the potential of a drug candidate to cause idiosyncratic drug reactions. Drug Discov Today 8 (2003) 832-837
215. Ekins S., Nikolsky Y., and Nikolskaya T. Techniques: Application of systems biology to absorption, distribution, metabolism, excretion, and toxicity. Trends Pharmacol Sci 26 (2005) 202-209
216. Rosipal R., and Trejo L. Kernel partial least squares regression in reproducing Kernel Hilbert space. J Mach Learn Res 2 (2001) 97-123
217. Bennett K., and Embrechts M. An optimization perspective on kernel partial least squares regression. In: Suykens J., Horvath G., Basu S., Micchelli J., and Vandewalle J. (Eds). Advances in Learning Theory; Methods, Models and Applications (2003), IOS Press, Amsterdam 227-250
218. Ekins S. Computer methods for predicting drug metabolism. In: Ekins S. (Ed). Computer Applications in Pharmaceutical Research and Development (2006), John Wiley and Sons, Hoboken 445-468
219. Leahy D. Drug discovery information integration: Virtual humans for pharmacokinetics. DDT: BIOSILICO 2 (2004) 78-84
220. Cook D., and Atkins W. Enhanced detoxication due to distributive catalysis and toxic thresholds: A kinetic analysis. Biochemistry 36 (1997) 10802-10806
221. Ekins S. Systems-ADME/Tox: Resources and network approaches. J Pharmacol Toxicol Methods 53 (2006) 38-66
222. Ekins S., and Giroux C. Computers and systems biology for pharmaceutical research and development. In: Ekins S. (Ed). Computer Applications in Pharmaceutical Research and Development (2006), John Wiley and Sons, Hoboken 139-165
223. Sin A., Chin K., Jamil M., Kostov Y., Rao G., and Shuler M. The design and fabrication of three-chamber microscale cell culture analog devices with integrated dissolved oxygen sensors. Biotechnol Prog 20 (2004) 338-345
224. Ertl P., Rohde B., and Selzer P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem 43 (2000) 3714-3717
225. Willet P. Similarity-based approaches to virtual screening. Biochem Soc Trans 31 (2003) 603-606
226. Nedelcheva V., and Gut I. P450 in the rat and man: Methods of investigation, substrate specificities and relevance to cancer. Xenobiotica 24 (1994) 1151-1175
227. Lee M., Park C., Dordick J., and Clark D. Metabolizing enzyme toxicology assay chip (MetaChip) for high-throughput microscale toxicity analyses. Proc Natl Acad Sci USA 102 (2005) 983-987
228. Zieziulewicz T., Unfricht D., Hadjout N., Lynes M., and Lawrence D. Shrinking the biologic world-nanobiotechnologies for toxicology. Toxicol Sci 74 (2003) 235-244
229. Glicklis R., Shapiro L., Agbaria R., Merchuk J., and Cohen S. Hepatocyte behavior within three-dimensional porous alginate scaffolds. Biotechnol Bioeng 67 (2000) 344-353
230. Dvir-Ginzberg M., Gamlieli-Bonshtein I., Agbaria R., and Cohen S. Liver tissue engineering within alginate scaffolds: Effects of cell-seeding density on hepatocyte viability, morphology, and function. Tissue Eng 9 (2003) 757-766
231. Powers M., Janigian D., Wack K., Baker C., Beer Stolz D., and Griffith L. Functional behavior of primary rat liver cells in a three-dimensional perfused microarray bioreactor. Tissue Eng 8 (2002) 499-513
232. Powers M., Domansky K., Kaazempur-Mofrad M., Kalezi A., Capitano A., Upadhyaya A., et al. A microfabricated array bioreactor for perfused 3D liver culture. Biotechnol Bioeng 78 (2002) 257-269
233. Viravaidya K., Sin A., and Shuler M. Development of a microscale cell culture analog to probe naphthalene toxicity. Biotechnol Prog 20 (2004) 316-323
234. Viravaidya K., and Shuler M. Incorporation of 3T3-L1 cells to mimic bioaccumulation in a microscale cell culture analog device for toxicity studies. Biotechnol Prog 20 (2004) 590-597
235. Li A., Bode C., and Sakai Y. A novel in vitro system, the integrated discrete multiple organ cell culture (IdMOC) system, for the evaluation of human drug toxicity: Comparative cytotoxicity of tamoxifen towards normal human cells from five major organs and MCF-7 adenocarcinoma breast cancer cells. Chem Biol Interact 150 (2004) 129-136
236. Leclerc E., Sakai Y., and Fujii T. Microfluidic PDMS (polydimethylsiloxane) bioreactor for large-scale culture of hepatocytes. Biotechnol Prog 20 (2004) 750-755
237. Fang Y., and Offenhaeusser A. ADMET biosensors: Up-to-date issues and strategies. Med Sci Monit 10 (2004) MT127-MT132
238. Andreescu S., and Sadik O. Advanced electrochemical sensors for cell cancer monitoring. Methods 37 (2005) 84-93
239. Garner R. Less is more: The human microdosing concept. Drug Discov Today 10 (2005) 449-451
240. Sandhu P., Vogel J., Rose M., Ubick E., Brunner J., Wallace M., et al. Evaluation of microdosing strategies for studies in preclinical drug development: Demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range. Drug Metab Dispos 32 (2004) 1254-1259
241. Sarapa N., Hsyu P., Lappin G., and Garner R. The application of accelerator mass spectrometry to absolute bioavailability studies in humans: Simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers. J Clin Pharmacol 45 (2005) 1198-1205
242. Huxley A., and Miles N. Alice Huxley and Nick Miles of Speedel on the company's pipeline and future plans. Interview by Christopher Watson and Stephen Carney. Drug Discov Today 10 (2005) 881-883
243. Walsky R., Gaman E., and Obach R. Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol 45 (2005) 68-78
244. Whelan K., and King R. Intelligent software for laboratory automation. Trends Biotechnol 22 (2004) 440-445
245. Ekins S., Boulanger B., Swaan P., and Hupcey M. Towards a new age of virtual ADME/TOX and multidimensional drug discovery. J Comput Aided Mol Des 16 (2002) 381-401
246. Shimada J., Ekins S., Elkin C., Shaknovich E., and Wery J. Integrating computer-based de novo drug design and multidimensional filtering for desirable drugs. Targets 1 (2002) 196-205
247. Dvorchik B. The disposition (ADME) of antisense oligonucleotides. Curr Opin Mol Ther 2 (2000) 253-257
248. Wroblewski V., Witcher D., Becker G., Davis K., Dou S., Micanovic R., et al. Decoy receptor 3 (DcR3) is proteolytically processed to a metabolic fragment having differential activities against Fas ligand and LIGHT. Biochem Pharmacol 65 (2003) 657-667
249. Wroblewski V., McCloud C., Davis K., Manetta J., Micanovic R., and Witcher D. Pharmacokinetics, metabolic stability, and subcutaneous bioavailability of a genetically engineered analog of DcR3, FLINT [DcR3(R218Q)], in cynomolgus monkeys and mice. Drug Metab Dispos 31 (2003) 502-507
250. Wroblewski V., Masnyk M., Khambatta S., and Becker G. Mechanisms involved in degradation of human insulin by cytosolic fractions of human, monkey, and rat liver. Diabetes 41 (1992) 539-547
251. Wroblewski V., Masnyk M., and Kaiser R. Metabolism of des(64,65)-human proinsulin in the rat. Evidence for the proteolytic processing to insulin. Diabetes 42 (1993) 1407-1414
252. Wroblewski V., Masnyk M., and Becker G. Proteolytic cleavage of human growth hormone (hGH) by rat tissues in vitro: Influence on the kinetics of exogenously administered hGH. Endocrinology 129 (1991) 465-474
253. Wroblewski V., Kaiser R., and Becker G. Proteolysis of human growth hormone by rat thyroid gland in vitro: Application of electrospray mass spectrometry and N-terminal sequencing to elucidate a metabolic pathway. Pharm Res 10 (1993) 1106-1114
254. Wroblewski V. Mechanism of deiodination of 125I-human growth hormone in vivo. Relevance to the study of protein disposition. Biochem Pharmacol 42 (1991) 889-897
255. Swaan P., and Ekins S. Reengineering the pharmaceutical industry by crash-testing molecules. Drug Discov Today 10 (2005) 1191-1200
256. Kim Y., and Ziegler D. Size limits of thiocarbamides accepted as substrates by human flavin-containing monooxygenase 1. Drug Metab Dispos 28 (2000) 1003-1006
257. Soffers A., Ploeman J., Moonen M., Wobbes T., van Ommen B., Vervoort J., et al. Regioselectivity and quantitative structure-activity relationships for the conjugation of a series of fluoronitrobenzenes by purified glutathione S-transferase enzymes from rat and man. Chem Res Toxicol 9 (1996) 638-646
258. Medvedev A., Veselovsky A., Shvedov V., Tikhonova O., Moskvitina T., Fedotova O., et al. Inhibition of monoamine oxidase by pirlindole analogues: 3D-QSAR and CoMFA analysis. J Chem Inf Comput Sci 38 (1998) 1137-1144
259. Miller J., and Edmondson D. Structure-activity relationships in the oxidation of para-substituted benzylamine analogues by recombinant human liver monoamine oxidase A. Biochemistry 38 (1999) 13670-13683
260. Ekins S., Waller C., Swaan P., Cruciani G., Wrighton S., and Wikel J. Progress in predicting human ADME parameters in silico. J Pharmacol Toxicol Methods 44 (2000) 251-272
261. Ganter B., Tugendreich S., Pearson C., Ayanoglu E., Baumhueter S., Bostian K., et al. Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action. J Biotechnol 119 (2005) 219-244
262. Edmondson D., Mattevi A., Binda C., Li M., and Hubalek F. Structure and mechanism of monoamine oxidase. Curr Med Chem 11 (2004) 1983-1993
263. Binda C., Hubalek F., Li M., Edmondson D., and Mattevi A. Crystal structure of human monoamine oxidase B, a drug target enzyme monotopically inserted into the mitochondrial outer membrane. FEBS Lett 564 (2004) 225-228
264. Binda C., Hubalek F., Li M., Herzig Y., Sterling J., Edmondson D., et al. Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class. J Med Chem 47 (2004) 1767-1774
265. Binda C., Li M., Hubalek F., Restelli N., Edmondson D., and Mattevi A. Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures. Proc Natl Acad Sci USA 100 (2003) 9750-9755
266. Cavalli A., Greco G., Novellino E., and Recanatini M. Linking CoMFA and protein homology models of enzyme-inhibitor interactions: An application to non-steroidal aromatase inhibitors. Bioorg Med Chem 8 (2000) 2771-2780
267. Sonnet P., Dallemagne P., Guillon J., Enguehard C., Stiebing S., Tanguy J., et al. New aromatase inhibitors, synthesis and biological activity of aryl-substituted pyrrolizine and indolizine derivatives. Bioorg Med Chem 8 (2000) 945-955
268. Laughton C., Zvelebil M., and Neidle S. A detailed molecular model for human aromatase. J Steroid Biochem Mol Biol 44 (1993) 399-407
269. Lewis D., and Lee-Robichaud P. Molecular modelling of steroidogenic cytochromes P450 from families CYP11, CYP17, CYP19 and CYP21 based on the CYP102 crystal structure. J Steroid Biochem Mol Biol 66 (1998) 217-233
270. Vanden Bossche H., Koymans L., and Moereels H. P450 inhibitors of use in medical treatment: Focus on mechanisms of action. Pharmacol Ther 67 (1995) 79-100
271. Buchwald P. Structure-metabolism relationships: Steric effects and the enzymatic hydrolysis of carboxylic esters. Mini Rev Med Chem 1 (2001) 101-111
272. Wadkins R., Hyatt J., Wei X., Yoon K., Wierdl M., Edwards C., et al. Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem 48 (2005) 2906-2915
273. Wadkins R., Hyatt J., Yoon K., Morton C., Lee R., Damodaran K., et al. Discovery of novel selective inhibitors of human intestinal carboxylesterase for the amelioration of irinotecan-induced diarrhea: Synthesis, quantitative structure-activity relationship analysis, and biological activity. Mol Pharmacol 65 (2004) 1336-1343
274. Knaak J., Dary C., Power F., Thompson C., and Blancato J. Physicochemical and biological data for the development of predictive organophosphorus pesticide QSARs and PBPK/PD models for human risk assessment. Crit Rev Toxicol 34 (2004) 143-207
275. Nakagawa Y., Wheelock C., Morisseau C., Goodrow M., Hammock B., and Hammock B. 3D-QSAR analysis of inhibition of murine soluble epoxide hydrolase (MsEH) by benzoylureas, arylureas, and their analogues. Bioorg Med Chem 8 (2000) 2663-2673
276. Devedjiev Y., Dauter Z., Kuznetsov S., Jones T., and Derewenda Z. Crystal structure of the human acyl protein thioesterase I from a single X-ray data set to 1.5 Å. Structure 8 (2000) 1137-1146
277. Bencharit S., Morton C., Xue Y., Potter P., and Redinbo M. Structural basis of heroin and cocaine metabolism by a promiscuous human drug-processing enzyme. Nat Struct Biol 10 (2003) 349-356
278. Redinbo M., Bencharit S., and Potter P. Human carboxylesterase 1: From drug metabolism to drug discovery. Biochem Soc Trans 31 (2003) 620-624
279. Bencharit S., Morton C., Hyatt J., Kuhn P., Danks M., Potter P., et al. Crystal structure of human carboxylesterase 1 complexed with the Alzheimer's drug tacrine: From binding promiscuity to selective inhibition. Chem Biol 10 (2003) 341-349
280. Fleming C., Bencharit S., Edwards C., Hyatt J., Tsurkan L., Bai F., et al. Structural insights into drug processing by human carboxylesterase 1: Tamoxifen, mevastatin, and inhibition by benzil. J Mol Biol 352 (2005) 165-177
281. Grimsley J., Calamini B., Wild J., and Mesecar A. Structural and mutational studies of organophosphorus hydrolase reveal a cryptic and functional allosteric-binding site. Arch Biochem Biophys 442 (2005) 169-179
282. McElroy N., Jurs P., Morisseau C., and Hammock B. QSAR and classification of murine and human epoxide hydrolase inhibition by urea-like compounds. J Med Chem 46 (2003) 1066-1080
283. Kim E., Kim K., and Shin W. Electrophysiological safety of DW-286a, a novel fluoroquinolone antibiotic agent. Hum Exp Toxicol 24 (2005) 19-25
284. Lewis D., Lake B., and Bird M. Molecular modelling of human microsomal epoxide hydrolase (EH) by homology with a fungal (Aspergillus niger) EH crystal structure of 1.8 Å resolution: Structure-activity relationships in epoxides inhibiting EH activity. Toxicol in vitro 19 (2005) 517-522
285. Gomez G., Morisseau C., Hammock B., and Christianson D. Structure of human epoxide hydrolase reveals mechanistic inferences on bifunctional catalysis in epoxide and phosphate ester hydrolysis. Biochemistry 43 (2004) 4716-4723
286. Hansch C., Klein T., McClarin J., Langridge R., and Cornell N. A quantitative structure-activity relationship and molecular graphics analysis of hydrophobic effects in the interactions of inhibitors with alcohol dehydrogenase. J Med Chem 29 (1986) 615-620
287. Kutsenko A., Kuznetsov D., Poroikov V., and Tumanian V. Mapping of active site of alcohol dehydrogenase with low-molecular ligands. Bioorg Khim 26 (2000) 179-186
288. Hurley T., Bosron W., Stone C., and Amzel L. Structures of three human beta alcohol dehydrogenase variants. Correlations with their functional differences. J Mol Biol 239 (1994) 415-429
289. Davis G., Bosron W., Stone C., Owusu-Dekyi K., and Hurley T. X-ray structure of human beta3beta3 alcohol dehydrogenase. The contribution of ionic interactions to coenzyme binding. J Biol Chem 271 (1996) 17057-17061
290. Xie P., Parsons S., Speckhard D., Bosron W., and Hurley T. X-ray structure of human class IV sigmasigma alcohol dehydrogenase. Structural basis for substrate specificity. J Biol Chem 272 (1997) 18558-18563
291. Yang Z., Bosron W., and Hurley T. Structure of human chi chi alcohol dehydrogenase: A glutathione-dependent formaldehyde dehydrogenase. J Mol Biol 265 (1997) 330-343
292. Hurley T., Steinmetz C., Xie P., and Yang Z. Three-dimensional structures of human alcohol dehydrogenase isoenzymes reveal the molecular basis for their functional diversity. Adv Exp Med Biol 414 (1997) 291-302
293. Niederhut M., Gibbons B., Perez-Miller S., and Hurley T. Three-dimensional structures of the three human class I alcohol dehydrogenases. Protein Sci 10 (2001) 697-706
294. Gibbons B., and Hurley T. Structure of three class I human alcohol dehydrogenases complexed with isoenzyme specific formamide inhibitors. Biochemistry 43 (2004) 12555-12562
295. Sipila J., and Taskinen J. CoMFA modeling of human catechol O-methyltransferase enzyme kinetics. J Chem Inf Comput Sci 44 (2004) 97-104
296. Taskinen J., Ethell B., Pihlavisto P., Hood A., Burchell B., and Coughtrie M. Conjugation of catechols by recombinant human sulfotransferases, UDP-glucuronosyltransferases, and soluble catechol O-methyltransferase: Structure-conjugation relationships and predictive models. Drug Metab Dispos 31 (2003) 1187-1197
297. Lee K., Fuda H., Lee Y., Negishi M., Strott C., and Pedersen L. Crystal structure of human cholesterol sulfotransferase (SULT2B1b) in the presence of pregnenolone and 3′-phosphoadenosine 5′-phosphate. Rationale for specificity differences between prototypical SULT2A1 and the SULT2BG1 isoforms. J Biol Chem 278 (2003) 44593-44599
298. Rehse P., Zhou M., and Lin S. Crystal structure of human dehydroepiandrosterone sulphotransferase in complex with substrate. Biochem J 364 (2002) 165-171
299. King R., Sharma V., Pedersen L., Kakuta Y., Negishi M., and Duffel M. Structure-function modeling of the interactions of the N-alkyl-N-hydroxyanilines with rat hepatic aryl sulfotransferase IV. Chem Res Toxicol 13 (2000) 1251-1258
300. Bidwell L., McManus M., Gaedigk A., Kakuta Y., Negishi M., Pedersen L., et al. Crystal structure of human catecholamine sulfotransferase. J Mol Biol 293 (1999) 521-530
301. Lautala P., Ulmanen I., and Taskinen J. Molecular mechanisms controlling the rate and specificity of catechol O-methylation by human soluble catechol O-methyltransferase. Mol Pharmacol 59 (2001) 393-402
302. Chen D., Wang C., Lambert J., Ai N., Welsh W., and Yang C. Inhibition of human liver catechol-O-methyltransferase by tea catechins and their metabolites: Structure-activity relationship and molecular-modeling studies. Biochem Pharmacol 69 (2005) 1523-1531
303. Ames M., Selassie C., Woodson L., Van Loon J., Hansch C., and Weinshilboum R. Thiopurine methyltransferase: Structure-activity relationships for benzoic acid inhibitors and thiophenol substrates. J Med Chem 29 (1986) 354-358
304. Mesangeau C., Yous S., Chavatte P., Ferry G., Audinot V., Boutin J., et al. Design, synthesis and in vitro evaluation of novel benzo[b]thiophene derivatives as serotonin N-acetyltransferase (AANAT) inhibitors. J Enzyme Inhib Med Chem 18 (2003) 119-125
305. Rodrigues-Lima F., and Dupret J. 3D model of human arylamine N-acetyltransferase 2: Structural basis of the slow acetylator phenotype of the R64Q variant and analysis of the active-site loop. Biochem Biophys Res Commun 291 (2002) 116-123
306. Rodrigues-Lima F., Delomenie C., Goodfellow G., Grant D., and Dupret J. Homology modelling and structural analysis of human arylamine N-acetyltransferase NAT1: Evidence for the conservation of a cysteine protease catalytic domain and an active-site loop. Biochem J 356 (2001) 327-334
307. Gu Y., Guo J., Pal A., Pan S., Zimniak P., Singh S., et al. Crystal structure of human glutathione S-transferase A3-3 and mechanistic implications for its high steroid isomerase activity. Biochemistry 43 (2004) 15673-15679
308. Le Trong I., Stenkamp R., Ibarra C., Atkins W., and Adman E. 1.3-Å resolution structure of human glutathione S-transferase with S-hexyl glutathione bound reveals possible extended ligandin binding site. Proteins 48 (2002) 618-627
309. Oakley A., Lo Bello M., Battistoni A., Ricci G., Rossjohn J., Villar H., et al. The structures of human glutathione transferase P1-1 in complex with glutathione and various inhibitors at high resolution. J Mol Biol 274 (1997) 84-100
310. Oakley A., Lo Bello M., Mazzetti A., Federici G., and Parker M. The glutathione conjugate of ethacrynic acid can bind to human pi class glutathione transferase P1-1 in two different modes. FEBS Lett 419 (1997) 32-36
311. Ji X., Tordova M., O'Donnell R., Parsons J., Hayden J., Gilliland G., et al. Structure and function of the xenobiotic substrate-binding site and location of a potential non-substrate-binding site in a class pi glutathione S-transferase. Biochemistry 36 (1997) 9690-9702
312. Ekins S., Kirillov E., Rakhmatulin E., and Nikolskaya T. A novel method for visualizing nuclear hormone receptor networks relevant to drug metabolism. Drug Metab Dispos 33 (2005) 474-481
313. Ekins S., Andreyev S., Ryabov A., Kirilov E., Rakhmatulin E., Bugrim A., et al. Computational prediction of human drug metabolism. Expert Opin Drug Metab Toxicol 1 (2005) 303-324
314. Thorn C., Klein T., Altman R., and Pharm G. The pharmacogenetics and pharmacogenomics knowledge base. Methods Mol Biol 311 (2005) 179-191
315. Schuetz E., Relling M., Kishi S., Yang W., Das S., Chen P., et al. PharmGKB update: II. CYP3A5, cytochrome P450, family 3, subfamily A, polypeptide 5. Pharmacol Rev 56 (2004) 159